Ricardo Invests in a Hydrogen Development and Testing Facility Leading the Way in the Future of Sustainable Transport
28.1.2021 03:01:00 EET | Business Wire | Press release
As part of its mission to support the decarbonisation of the global transport and energy sectors, Ricardo, a world-class environmental, engineering and strategic consulting company, has today announced an initial investment of £2.5million to build a hydrogen development and test facility at its Shoreham Technical Centre in the UK.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210127006018/en/
Hydrogen-fuel cell (Photo: Business Wire)
Designed to support the company’s existing work in hydrogen, fuel cells and green alternative fuels, the new facility will deliver state-of-the-art test and development to advance capability in both alternative fuels and electric vehicles. It will significantly increase the range of hydrogen and fuel cell services and solutions which can be delivered to Ricardo’s global customers.
Steve Dyke, Managing Director of Ricardo Automotive and Industrial said: “We are already working with a range of clients on hydrogen and fuel cell technology, providing clean efficient solutions which reduce carbon and noxious emissions across a wide range of sectors. By building our hydrogen fuel cell and propulsion capability, we shall further advance our facilities and technology for clean vehicles across all transport sectors, and increase the range of hydrogen and fuel cell services and solutions that we can offer to our clients.
“A particular focus for the new facility will be a systems-led approach to vehicle development, integrating our enhanced test capability with our leading-edge digital and simulation tools to deliver fully optimised hardware and software system solutions for our customers. This will further enhance our established digital engineering expertise, allowing the company to provide solutions which: are greener because they are less energy and resource-intensive; remove risk from development through more efficient, faster digital techniques; and reduce cost and time to market to provide competitive advantage.”
This investment is a further boost to Ricardo’s hydrogen capability, following the company’s announcement on 14 January 2021 of a collaboration with AFC Energy plc aimed at identifying new and innovative alternative fuel solutions, including hydrogen power applications.
Fuel cell test facilities with this level of capability to develop and test hydrogen technologies are rare across the globe, so this investment will accelerate Ricardo’s position as a leader in hydrogen transport technology.
Ends
About Ricardo
Ricardo plc is a world-class environmental, engineering and strategic consulting company listed on the London Stock Exchange. With over 100 years of engineering excellence, we provide exceptional levels of expertise in delivering leading edge and innovative cross sector sustainable products and solutions, helping our global customers increase efficiencies, achieve growth and create a clear and safer future. Our mission is clear -- to create a world fit for the future. For more information visit www.ricardo.com
About Ricardo Automotive and Industrial Division
Ricardo Automotive & Industrial Ricardo Automotive and Industrial, a division of Ricardo plc, provides global engineering services for OEMs across all transport sectors. The vision is to be the consulting partner of choice for clean efficient, integrated propulsion and energy solutions, underpinned by digitisation.
Ricardo is a supporter of the UK Hydrogen Strategy Now campaign. This group of leading UK businesses which has together committed to invest £3bn into hydrogen projects is calling on the Chancellor of the Exchequer for a UK-wide hydrogen strategy.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210127006018/en/
Contact information
For Ricardo:
Kathryn Bellamy
Communications Manager
Ricardo Automotive & Industrial, and Performance Products
Email: kathryn.bellamy@ricardo.com
Telephone: +44(0)7921 941824
Ricardo Media Office
Gill Gibbons
Email: media@ricardo.com
Telephone: +44 (0) 7795 342804
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 11:16:00 EEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom